Nkarta Stock Price, News & Analysis (NASDAQ:NKTX) $2.48 +0.02 (+0.81%) (As of 12:22 PM ET) Add Compare Share Share Today's Range$2.47▼$2.6150-Day Range$1.31▼$3.1452-Week Range$1.28▼$9.20Volume123,963 shsAverage Volume1.05 million shsMarket Capitalization$121.69 millionP/E RatioN/ADividend YieldN/APrice Target$14.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Nkarta MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside491.4% Upside$14.67 Price TargetShort InterestBearish14.39% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.50) to ($2.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.15 out of 5 starsMedical Sector423rd out of 949 stocksPharmaceutical Preparations Industry191st out of 438 stocks 3.5 Analyst's Opinion Consensus RatingNkarta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.67, Nkarta has a forecasted upside of 491.4% from its current price of $2.48.Amount of Analyst CoverageNkarta has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.39% of the outstanding shares of Nkarta have been sold short.Short Interest Ratio / Days to CoverNkarta has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nkarta has recently increased by 1.73%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNkarta does not currently pay a dividend.Dividend GrowthNkarta does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NKTX. Previous Next 2.7 News and Social Media Coverage News SentimentNkarta has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nkarta this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for NKTX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nkarta insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of Nkarta is held by insiders.Percentage Held by Institutions80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Nkarta are expected to grow in the coming year, from ($2.50) to ($2.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nkarta is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nkarta is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNkarta has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nkarta Stock (NASDAQ:NKTX)Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Read More NKTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKTX Stock News HeadlinesNovember 14, 2023 | finance.yahoo.comT. Rowe Price Investment Management, Inc. Reduces Stake in Nkarta IncNovember 11, 2023 | benzinga.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Nkarta, Inc. (NASDAQ: NKTX) and Encourages Investors to Contact the FirmNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 10, 2023 | markets.businessinsider.comPromising Developments and Financial Stability Propel Nkarta’s Buy Rating: An Insight into Expansion, Upcoming Trials, and Financial PositionNovember 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Adaptimmune Therapeutics (ADAP) and Corvus Pharmaceuticals (CRVS)November 10, 2023 | finanznachrichten.deNkarta, Inc.: Nkarta Reports Third Quarter 2023 Financial Results and Corporate HighlightsNovember 9, 2023 | finance.yahoo.comNkarta Reports Third Quarter 2023 Financial Results and Corporate HighlightsOctober 18, 2023 | msn.comRaymond James Upgrades Nkarta (NKTX)November 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 18, 2023 | finance.yahoo.comNkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus DrugOctober 17, 2023 | msn.comNkarta upgraded to strong buy by Raymond JamesOctober 17, 2023 | msn.comNkarta stock jumps 20% on FDA, cash runway extension updatesOctober 17, 2023 | bizjournals.comPeninsula biotech's stock soars as it cuts staff, focuses cell therapy on autoimmune diseasesOctober 17, 2023 | markets.businessinsider.comPositive Outlook for Nkarta: FDA Approvals, Cost Reduction Initiatives, and Promising Expansion into Autoimmune Disease TreatmentOctober 17, 2023 | benzinga.comNkarta Receives FDA Clearance of IND Application for NKX019 in Lupus NephritisOctober 17, 2023 | msn.comWhat's Going With Cancer-Focused Nkarta Stock Today?October 17, 2023 | markets.businessinsider.comNkarta’s Promising Pipeline Expansion and Cost-Saving Measures Drive Analyst’s Buy RatingOctober 17, 2023 | finance.yahoo.comLupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus NephritisOctober 17, 2023 | finanznachrichten.deNkarta, Inc.: Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus NephritisOctober 17, 2023 | markets.businessinsider.comNkarta Says FDA Clears IND Application For NKX019 To Treat Lupus NephritisOctober 16, 2023 | finance.yahoo.comNkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost MeasuresOctober 16, 2023 | finance.yahoo.comIs Nkarta (NASDAQ:NKTX) In A Good Position To Deliver On Growth Plans?October 9, 2023 | markets.businessinsider.comVentyx Biosciences Announces Positive Results From Trial Of VTX002 For Ulcerative ColitisSeptember 28, 2023 | markets.businessinsider.comPromising Prospects for Ventyx Biosciences: A Comprehensive Analysis of VTX002’s Potential in Ulcerative Colitis TreatmentSeptember 9, 2023 | benzinga.comNkarta Stock (NASDAQ:NKTX), Analyst Ratings, Price Targets, PredictionsAugust 14, 2023 | nasdaq.comMizuho Maintains Nkarta (NKTX) Buy RecommendationAugust 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Ventyx Biosciences (VTYX)See More Headlines Receive NKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NKTX CUSIPN/A CIK1787400 Webwww.nkartatx.com Phone925-407-1049FaxN/AEmployees167Year FoundedN/APrice Target and Rating Average Stock Price Target$14.67 High Stock Price Target$26.00 Low Stock Price Target$9.00 Potential Upside/Downside+496.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-36.69% Return on Assets-27.71% Debt Debt-to-Equity RatioN/A Current Ratio10.97 Quick Ratio10.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.05 per share Price / Book0.41Miscellaneous Outstanding Shares49,070,000Free Float46,324,000Market Cap$120.71 million OptionableNot Optionable Beta-0.11 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Paul J. Hastings (Age 63)CEO, President & Director Comp: $938.41kDr. Alicia J. Hager (Age 53)Chief Legal Officer & Corporate Secretary Comp: $590.94kMs. Alyssa Levin C.A. (Age 38)CPA, Chief Financial & Business Officer and Principal Accounting Officer Dr. Ralph Brandenberger Ph.D. (Age 54)Chief Technical Officer Dr. James Trager Ph.D. (Age 60)Chief Scientific Officer Mr. Greg MannVice President of Public Affairs and Investor RelationsDr. David R. Shook M.D. (Age 45)Chief Medical Officer More ExecutivesKey CompetitorsGalectin TherapeuticsNASDAQ:GALTAbeona TherapeuticsNASDAQ:ABEODesign TherapeuticsNASDAQ:DSGNCitius PharmaceuticalsNASDAQ:CTXRVaxxinityNASDAQ:VAXXView All CompetitorsInsiders & InstitutionsStifel Financial CorpBought 263,302 shares on 11/13/2023Ownership: 1.073%Northern Trust CorpBought 5,717 shares on 11/13/2023Ownership: 0.658%Acadian Asset Management LLCBought 64,549 shares on 11/13/2023Ownership: 0.132%Mariner LLCBought 10,330 shares on 11/13/2023Ownership: 0.063%Innovis Asset Management LLCBought 138,962 shares on 11/9/2023Ownership: 0.283%View All Insider TransactionsView All Institutional Transactions NKTX Stock Analysis - Frequently Asked Questions Should I buy or sell Nkarta stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NKTX shares. View NKTX analyst ratings or view top-rated stocks. What is Nkarta's stock price target for 2024? 5 analysts have issued twelve-month price objectives for Nkarta's stock. Their NKTX share price targets range from $9.00 to $26.00. On average, they expect the company's share price to reach $14.67 in the next year. This suggests a possible upside of 491.4% from the stock's current price. View analysts price targets for NKTX or view top-rated stocks among Wall Street analysts. How have NKTX shares performed in 2023? Nkarta's stock was trading at $5.99 at the beginning of 2023. Since then, NKTX stock has decreased by 58.6% and is now trading at $2.48. View the best growth stocks for 2023 here. When is Nkarta's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our NKTX earnings forecast. How were Nkarta's earnings last quarter? Nkarta, Inc. (NASDAQ:NKTX) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.06. What other stocks do shareholders of Nkarta own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), Salesforce (CRM), CVS Health (CVS) and DraftKings (DKNG). When did Nkarta IPO? (NKTX) raised $150 million in an IPO on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities acted as the underwriters for the IPO. Who are Nkarta's major shareholders? Nkarta's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stifel Financial Corp (1.07%), Northern Trust Corp (0.66%), Monaco Asset Management SAM (0.48%), Innovis Asset Management LLC (0.28%), New York Life Investment Management LLC (0.20%) and Charles Schwab Investment Management Inc. (0.14%). Insiders that own company stock include David Shook, Dawn N Edwards, James Trager, Kanya Rajangam, Nadir Mahmood, Paul J Hastings, Paul J Hastings, Ra Capital Management, LP, Ralph Brandenberger and Simeon George. View institutional ownership trends. How do I buy shares of Nkarta? Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:NKTX) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.